Effect of Ranolazine in Patients with Chest Pain and Normal Coronaries- A Hospital Based Study

Health-Related Quality of Life at 30 Days Among Indian Patients With Acute Myocardial Infarction

“…Previous studies evaluating health-related quality of life in India have included fewer than 100 participants each, and no study had more than 25 women. [11][12][13][14] Three of these studies that evaluated quality of life were among military veterans after revascularization (2 studies) and patients with coronary artery disease and panic disorder treated at a north Indian government hospital (1 study), and they demonstrated more angina, lower quality of life and lower treatment satisfaction than in participants in our study. [12][13][14] On the other hand, our results were similar to baseline health-related quality of life estimates from a 2017 Indian trial evaluating the effect of ranolazine among individuals with microvascular dysfunction.…”

“…[12][13][14] On the other hand, our results were similar to baseline health-related quality of life estimates from a 2017 Indian trial evaluating the effect of ranolazine among individuals with microvascular dysfunction. 11 Data from the 2003-2004 Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER, n= 1,815 participants) in the United States demonstrated that 27% and 24% of post-myocardial infarction patients had angina at 1-and 6-month followup, respectively, 15 which were lower than angina rates from ACS QUIK. In the PREMIER study, individuals with persistent angina were three times more likely to report low treatment satisfaction, even after multivariable adjustment.…”

Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction—A Systematic Review and Meta-analysis of Randomized Trials

“…Several studies have lately evaluated the value of ranolazine in patients with CMD, showing some inconsistencies in terms of its magnitude and direction of the effect. [7][8][9][10][11][12][13] Therefore, we conducted a systematic review and meta-analysis including all randomized trials assessing the efficacy of ranolazine in patients with CMD.…”

“…16 In general, CMD was defined as ischemic heart disease in the absence of obstructed coronary arteries: no coronary artery stenosis > 50%-70% or coronary lesions with a fractional flow reserve value <0.8, if available. 5,[7][8][9][10][11][12] Of note, only 1 study enrolled patients with coronary artery stenosis up to 70%. 9 In the included studies, cardiac ischemia was assessed by (1) exercise stress-testing, 10 (2) cardiac magnetic resonance tomography, 7,8 or (3) nuclear imaging modalities (single photon emission computed tomography or positron emission tomography/computed tomography).…”

Differentiated approach in diagnostics, diagnosis formulation, case management and statistical accounting of type 2 myocardial infarction (Position Paper)

“…Среди стандартных антиангинальных препаратов эффективны блокаторы кальциевых каналов и β-блокаторы, менее эффективны -нитраты [40]. Кроме того, в небольших рандомизированных конт-ролируемых КИ была продемонстрирована эффективность других антиангинальных препаратов, механизм действия которых связан с улучшением эндотелиальной функции (например, L-аргинин [41], статины [42], эналаприл [43]), микрососудистой вазодилатацией (дипиридамол [44], ранолазин [45]), или с висцеральным анальгетическим эффектом (имипрамин [46], аминофиллин [47]). Ограничением данных исследований является то, что ИМ в них был критерием исключения, поэтому необходимо проведение отдельных КИ для ИМ с патогенезом коронарной микрососудистой дисфункции [33].…”